ELOX vs. ALBT, FNCH, GMDAQ, KRBP, WINT, TCBP, TCON, SCNI, FRTX, and NSTGQ
Should you be buying Eloxx Pharmaceuticals stock or one of its competitors? The main competitors of Eloxx Pharmaceuticals include Avalon GloboCare (ALBT), Finch Therapeutics Group (FNCH), Gamida Cell (GMDAQ), Kiromic BioPharma (KRBP), Windtree Therapeutics (WINT), TC Biopharm (TCBP), TRACON Pharmaceuticals (TCON), Scinai Immunotherapeutics (SCNI), Fresh Tracks Therapeutics (FRTX), and NanoString Technologies (NSTGQ). These companies are all part of the "biological products, except diagnostic" industry.
Eloxx Pharmaceuticals (NASDAQ:ELOX) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation, community ranking and institutional ownership.
Eloxx Pharmaceuticals has a beta of 2.71, indicating that its share price is 171% more volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.
Eloxx Pharmaceuticals presently has a consensus target price of $55.00, suggesting a potential upside of 6,011.11%. Given Eloxx Pharmaceuticals' higher possible upside, analysts clearly believe Eloxx Pharmaceuticals is more favorable than Avalon GloboCare.
Avalon GloboCare has higher revenue and earnings than Eloxx Pharmaceuticals. Avalon GloboCare is trading at a lower price-to-earnings ratio than Eloxx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Eloxx Pharmaceuticals had 2 more articles in the media than Avalon GloboCare. MarketBeat recorded 2 mentions for Eloxx Pharmaceuticals and 0 mentions for Avalon GloboCare. Avalon GloboCare's average media sentiment score of 0.98 beat Eloxx Pharmaceuticals' score of 0.00 indicating that Avalon GloboCare is being referred to more favorably in the news media.
2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 20.2% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 64.0% of Avalon GloboCare shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Eloxx Pharmaceuticals received 13 more outperform votes than Avalon GloboCare when rated by MarketBeat users.
Eloxx Pharmaceuticals has a net margin of 0.00% compared to Avalon GloboCare's net margin of -1,304.14%.
Summary
Eloxx Pharmaceuticals beats Avalon GloboCare on 7 of the 13 factors compared between the two stocks.
Get Eloxx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eloxx Pharmaceuticals Competitors List
Related Companies and Tools
